Teva lures former Merck SVP to its executive team

15 May 2024

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) has appointed Matthew Shields as executive vice president of Teva Global Operations (TGO), the company’s manufacturing and supply division, effective June 3, 2024.

Mr Shields succeeds Eric Drapé, who is leaving after 11 years with Teva, including more than four years as EVP global operations. Mr Shields will be a member of Teva’s executive leadership Team and report directly to president and chief executive Richard Francis. He will be based in Teva’s US headquarters in Parsippany, NJ.

Mr Shields joins Teva with a track record over a 25-plus year career in the global biopharmaceutical and animal health industries. As an engineer by trade, he brings significant experience at every stage of the manufacturing and supply process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK